Bio and nanotechnological strategies for tumor-targeted gene therapy.

Gene therapy is a new medical approach for the treatment of tumors. For safe and efficient gene therapy, therapeutic genes need to be delivered efficiently into the target tumor cells. Development of gene delivery systems to specifically recognize and target tumor cells and to distinguish them from normal cells, especially in the same tissue or organ, is one of the most important issues regarding the present gene delivery methodologies. The enhanced permeability and retention (EPR) effect using the characteristics of angiogenic tumor blood vessels, as well as gene delivery systems recognizing hyperactivated receptors or intracellular signals, is broadly applied to tumor-targeted gene therapy. In addition, bacterial vectors can be a useful means for targeting hypoxic or anoxic regions of a tumor.

[1]  Mark E. Davis,et al.  Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. , 2003, Bioconjugate chemistry.

[2]  Leaf Huang,et al.  Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. , 2009, Molecular pharmaceutics.

[3]  J. Hofmann.  Protein kinase C isozymes as potential targets for anticancer therapy. , 2004, Current cancer drug targets.

[4]  N. M. Rao,et al.  Haloperidol-associated Stealth Liposomes , 2005, Journal of Biological Chemistry.

[5]  C. Southan.  A genomic perspective on human proteases , 2001, FEBS letters.

[6]  E. Aydar,et al.  Sigma Receptors and Cancer , 2004, Cancer Research.

[7]  Leaf Huang,et al.  An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[8]  M. Tangney,et al.  Viral vectors in cancer immunotherapy: which vector for which strategy? , 2008, Current gene therapy.

[9]  G. Navarro,et al.  In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma , 2009, The journal of gene medicine.

[10]  T. Niidome,et al.  An intracellular kinase signal-responsive gene carrier for disordered cell-specific gene therapy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[11]  T. Niidome,et al.  Cellular signal-specific peptide substrate is essential for the gene delivery system responding to cellular signals. , 2009, Bioorganic & medicinal chemistry letters.

[12]  T. Minko,et al.  Antibodies and peptides in cancer therapy. , 2006, Critical reviews in therapeutic drug carrier systems.

[13]  G. Prestwich,et al.  Cancer-targeted polymeric drugs. , 2002, Current cancer drug targets.

[14]  T. Park,et al.  Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. , 2008, Biochemical and biophysical research communications.

[15]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[16]  Y. Maitani,et al.  Effect of Polyethylene Glycol Linker Chain Length of Folate-Linked Microemulsions Loading Aclacinomycin A on Targeting Ability and Antitumor Effect In vitro and In vivo , 2005, Clinical Cancer Research.

[17]  D. Saint-Dic,et al.  Microbial based therapy of cancer: A new twist to an age old practice , 2004, Cancer biology & therapy.

[18]  K. Ulbrich,et al.  Retargeting polymer‐coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer , 2008, The journal of gene medicine.

[19]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[20]  M. Ratnam,et al.  The folate receptor: What does it promise in tissue-targeted therapeutics? , 2007, Cancer and Metastasis Reviews.

[21]  S. Wadsworth,et al.  Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  J. Schlessinger,et al.  Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring , 2006, Cell.

[23]  Ming Yao,et al.  Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  J. Vermorken,et al.  Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. , 2007, The oncologist.

[25]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[26]  Kit S Lam,et al.  From combinatorial chemistry to cancer-targeting peptides. , 2007, Molecular pharmaceutics.

[27]  I. Khalil,et al.  Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery , 2006, Pharmacological Reviews.

[28]  T. Niidome,et al.  Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[29]  B. S. Reddy,et al.  17β‐Estradiol‐Associated Stealth‐Liposomal Delivery of Anticancer Gene to Breast Cancer Cells , 2005 .

[30]  T. Niidome,et al.  Protein kinase Cα‐responsive polymeric carrier: its application for gene delivery into human cancers , 2009, Cancer science.

[31]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Niidome,et al.  Hepatoma-targeted gene delivery using a tumor cell-specific gene regulation system combined with a human liver cell-specific bionanocapsule. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[33]  M. Wei,et al.  Bacterial targeted tumour therapy-dawn of a new era. , 2008, Cancer letters.

[34]  Jun Fang,et al.  Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.

[35]  P. Attwood,et al.  Mammalian histidine kinases. , 2005, Biochimica et biophysica acta.

[36]  L. Kelemen,et al.  The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander? , 2006, International journal of cancer.

[37]  C. Cho,et al.  Receptor-mediated gene delivery by folate-PEG-baculovirus in vitro. , 2007, Journal of biotechnology.

[38]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[39]  W. Miller,et al.  Processive phosphorylation: mechanism and biological importance. , 2007, Cellular signalling.

[40]  E. Chowdhury.  Nuclear targeting of viral and non-viral DNA , 2009, Expert opinion on drug delivery.

[41]  A. Beer,et al.  Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. , 2009, Frontiers in bioscience.

[42]  V. Krasnykh,et al.  Modification of Adenovirus Capsid with a Designed Protein Ligand Yields a Gene Vector Targeted to a Major Molecular Marker of Cancer , 2007, Journal of Virology.

[43]  Kazunori Kataoka,et al.  Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. , 2005, Journal of the American Chemical Society.

[44]  A. Nebreda,et al.  Protein kinases and phosphatases as therapeutic targets in cancer , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[45]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[46]  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. , 2008, Expert opinion on drug delivery.

[47]  N. Minton.  Clostridia in cancer therapy , 2003, Nature Reviews Microbiology.

[48]  H. Mackay,et al.  Targeting the protein kinase C family: are we there yet? , 2007, Nature Reviews Cancer.

[49]  Jianren Gu,et al.  A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2. , 2004, Biochemical and biophysical research communications.

[50]  K. Ulbrich,et al.  Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via α6-integrins , 2007, Cancer Gene Therapy.

[51]  R K Jain,et al.  Vascular permeability in a human tumour xenograft: molecular charge dependence , 2000, British Journal of Cancer.

[52]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[53]  T. Niidome,et al.  A protein kinase signal-responsive gene carrier modified RGD peptide. , 2006, Bioorganic & medicinal chemistry letters.

[54]  Z. Lu,et al.  Water soluble polymers in tumor targeted delivery. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[55]  Mizuo Maeda,et al.  Intracellular signal-responsive artificial gene regulation for novel gene delivery. , 2002, Biomacromolecules.

[56]  T. Niidome,et al.  Protein kinase C alpha-specific peptide substrate graft-type copolymer for cancer cell-specific gene regulation systems. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[57]  T. Niidome,et al.  Intracellular signal-responsive gene carrier for cell-specific gene expression. , 2005, Biomacromolecules.

[58]  T. Niidome,et al.  Design of polymeric carriers for cancer-specific gene targeting: utilization of abnormal protein kinase Calpha activation in cancer cells. , 2008, Journal of the American Chemical Society.

[59]  K. Williams,et al.  Gene therapy approaches to enhance bioreductive drug treatment. , 2008, The British journal of radiology.

[60]  J. Leroux,et al.  Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[61]  E. Wagner,et al.  An acetal-based PEGylation reagent for pH-sensitive shielding of DNA polyplexes. , 2007, Bioconjugate chemistry.

[62]  Y. Maitani,et al.  Folate-linked lipid-based nanoparticle for targeted gene delivery. , 2005, Current drug delivery.

[63]  P. Swaan,et al.  Endocytic mechanisms for targeted drug delivery. , 2007, Advanced drug delivery reviews.

[64]  T. Niidome,et al.  Inflammatory cell‐specific transgene expression system responding to Iκ‐B kinase beta activation , 2009, The journal of gene medicine.

[65]  Erwin G. Van Meir,et al.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. , 2007, Cancer research.

[66]  T. Niidome,et al.  A short peptide is a protein kinase C (PKC) α‐specific substrate , 2008, Proteomics.

[67]  Won-Kyung Cho,et al.  Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[69]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[70]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[71]  F. Errington,et al.  Oncolytic viruses: a novel form of immunotherapy , 2008, Expert review of anticancer therapy.

[72]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[73]  M. Futai,et al.  Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. , 2003, Cell structure and function.

[74]  H. Maeda,et al.  Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application , 2009, Cancer science.

[75]  Olivia M Merkel,et al.  Integrin alphaVbeta3 targeted gene delivery using RGD peptidomimetic conjugates with copolymers of PEGylated poly(ethylene imine). , 2009, Bioconjugate chemistry.

[76]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[77]  Vladimir P Torchilin,et al.  Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[78]  Vladimir P. Torchilin,et al.  Polyethylene Glycol-Diacyllipid Micelles Demonstrate Increased Accumulation in Subcutaneous Tumors in Mice , 2002, Pharmaceutical Research.

[79]  P. Steeg,et al.  Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. , 2003, Cancer letters.

[80]  J. Anné,et al.  The use of clostridial spores for cancer treatment , 2006, Journal of applied microbiology.

[81]  R. Nicholson,et al.  Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. , 2005, Endocrine-related cancer.

[82]  M. Lübbert,et al.  Leukemia targeting ligands isolated from phage display peptide libraries , 2007, Leukemia.

[83]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[84]  J. M. Kumar,et al.  Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.